论文部分内容阅读
目的:探讨盐酸替罗非班治疗冠心病的临床价值。方法:选择冠心病患者90例,根据入院顺序将其分为治疗组与对照组,各45例,在常规药物与PCI治疗的基础上,治疗组在PCI术中给予盐酸替罗非班治疗,对照组给予低分子肝素治疗。结果:两组都无死亡与大量出血情况发生,治疗组新近心肌梗死、顽固缺血状态与少量出血的发生率明显少于对照组(P<0.05)。结论:盐酸替罗非班是一种短效、高选择性的糖蛋白受体拮抗剂,可快速减少住院期间的主要心血管不良事件,具有较好的耐受性和安全性。
Objective: To investigate the clinical value of tirofiban hydrochloride in the treatment of coronary heart disease. Methods: Ninety patients with coronary heart disease were selected and divided into treatment group and control group according to admission order. Each group was given 45 cases, on the basis of conventional drugs and PCI, the treatment group was treated with tirofiban hydrochloride during PCI, Control group given low molecular weight heparin treatment. Results: There was no death or massive bleeding in both groups. The incidence of myocardial infarction, intractable ischemia and bleeding in the treatment group was significantly less than that in the control group (P <0.05). Conclusion: Tirofiban Hydrochloride is a short-acting and highly selective glycoprotein receptor antagonist, which can rapidly reduce the major cardiovascular adverse events during hospitalization and has good tolerance and safety.